-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA: APPROVES NEW STARTING DOSAGE REGIMEN FOR LEQEMBI SUBCUTANEOUS FORMULATION FOR ALZHEIMER’S DISEASE TREATMENT

路透·07/13/2026 18:07:27

登錄查看新聞詳情